Apogee Therapeutics Inc. (APGE)

Apogee Therapeutics (NASDAQ:APGE) Trading Down 4% - Defense World

Defense World

SQZ Biotechnologies (NYSE:SQZ) & Apogee Therapeutics (NASDAQ:APGE) Head-To-Head Review - Defense World

Defense World

Apogee Therapeutics (NASDAQ:APGE) Shares Down 4% - MarketBeat

MarketBeat

New York State Common Retirement Fund Has $251000 Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World

Defense World

Apogee Therapeutics, Inc. (NASDAQ:APGE) Short Interest Up 6.4% in April - MarketBeat

MarketBeat

Apogee Therapeutics, Inc. (NASDAQ:APGE) Short Interest Update - Defense World

Defense World

Apogee Therapeutics Inc. (APGE) can make a big difference with a little luck – Sete News - SETE News

SETE News

Research Analysts Set Expectations for Apogee Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:APGE) - Defense World

Defense World

Apogee Therapeutics Starts Phase 2 Trial for Atopic Dermatitis Drug - TipRanks.com - TipRanks

TipRanks

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half ... - GlobeNewswire

GlobeNewswire

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

GlobeNewswire Inc.

Wedbush Comments on Apogee Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:APGE) - MarketBeat

MarketBeat

Wedbush Reiterates “Outperform” Rating for Apogee Therapeutics (NASDAQ:APGE) - Defense World

Defense World

Apogee Therapeutics (NASDAQ:APGE) Sees Large Volume Increase - MarketBeat

MarketBeat

Apogee Therapeutics, Inc. to Post Q1 2025 Earnings of ($0.63) Per Share, Wedbush Forecasts (NASDAQ:APGE) - MarketBeat

MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Stock Rating Reaffirmed by Wedbush - MarketBeat

MarketBeat

Stifel maintains buy on Apogee Therapeutics stock By Investing.com - Investing.com

Investing.com

Apogee Therapeutics selects APG-990 development candidate for atopic dermatitis - BioWorld Online

BioWorld Online

Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results - ForexTV.com

ForexTV.com

Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results - Yahoo Finance

Yahoo Finance

Apogee Therapeutics (NASDAQ:APGE) Research Coverage Started at Bank of America - Defense World

Defense World

Apogee Therapeutics (NASDAQ:APGE) Shares Gap Up to $52.92 - Defense World

Defense World

Apogee Therapeutics (NASDAQ:APGE) Shares Gap Up to $52.92 - MarketBeat

MarketBeat

B of A Securities Initiates Coverage of Apogee Therapeutics (APGE) with Buy Recommendation - MSN

MSN

Bank of America Initiates Coverage on Apogee Therapeutics (NASDAQ:APGE) - MarketBeat

MarketBeat

Bank of America Initiates Coverage on Apogee Therapeutics (NASDAQ:APGE) - MarketBeat

MarketBeat

Earnings Superstars: 3 Stocks Primed to Outperform This Quarter - InvestorPlace

InvestorPlace

Earnings Superstars: 3 Stocks Primed to Outperform This Quarter - InvestorPlace

InvestorPlace

Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference - Marketscreener.com

Marketscreener.com

Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference - Yahoo Finance

Yahoo Finance

Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference - Yahoo Finance

Yahoo Finance

Apogee Therapeutics Insider Ups Holding During Year - Simply Wall St

Simply Wall St

Apogee Therapeutics (NASDAQ:APGE) Stock Price Down 6.1% - MarketBeat

MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Trading Up 3.3% - MarketBeat

MarketBeat

Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why

Zacks Investment Research

Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why - Yahoo Finance

Yahoo Finance

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases

GlobeNewswire Inc.

Apogee Therapeutics Launches Innovative Antibody Clinical Trial - TipRanks.com - TipRanks

TipRanks

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs

Benzinga

Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million

GlobeNewswire Inc.

Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option ... - GlobeNewswire

GlobeNewswire

Public equity report: Boundless to test IPO appetite as follow-ons continue to deliver - BioCentury

BioCentury

Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering

GlobeNewswire Inc.

Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering - GlobeNewswire

GlobeNewswire

Clinical report: Akero's efruxifermin shows deepening treatment effect at 96 weeks - BioCentury

BioCentury

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

GlobeNewswire Inc.

Crude Oil Down 1%; Dave Shares Jump After Q4 Results

Benzinga

Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Nasdaq Down 250 Points; ISM Services PMI Falls In February

Benzinga

NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday

Benzinga